Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Variegate Porphyria (VP)-related skin disease

Next Previous
X
Search
Trial Profile

A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Variegate Porphyria (VP)-related skin disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afamelanotide (Primary)
  • Indications Variegate-porphyria
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Phase IIa VP Study
  • Sponsors Clinuvel Pharmaceuticals

    • Most Recent Events

    • 20 Sep 2024 According to a Clinuvel Pharmaceuticals media release, data on long-term use of drug SCENESSE (afamelanotide 16mg) as a first-in-line photoprotective treatment for porphyrias will be presented at the International Congress of Porphyrins and Porphyrias (ICPP 2024), which runs from 21-25 Sep in Pamplona, Spain.
    • 24 Jan 2024 Status changed from active, no longer recruiting to completed.
    • 10 Oct 2023 According to a Clinuvel Pharmaceuticals media release, outcomes from this study is expected in next year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top